Y. Mangan

Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex)

Karmen Iessa, Kavita Kantilal, Ieda Garekyaragh, Lucy Paget et autres

Melanoma is an aggressive type of skin cancer. Immune checkpoint inhibitors (ICIs): pembrolizumab, ipilimumab and/or nivolumab are recommended for the treatment of metastatic melanoma. ICIs enhance the immune response by blocking PD-1 and/or CTLA-4, improving remission and overall survival (OS). However, ICIs …

gb (code pays fourni par la source)

P3.14.05 Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatments

Michele Maffezzoli, James Siu Ki Lau, Hayati Mohd Yusof, Judith Cave et autres

it, gb, us (code pays fourni par la source)

240P: Real-world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma across 11 UK centres

H McGrath, M. Elgendy, Laura J. Gray, Aitzaz Qaisar et autres

gb (code pays fourni par la source)

1215P United Kingdom (UK) real world study of adjuvant osimertinib in resected EGFR mutated lung cancer

Raghad Elghadi, Indrani Datta, Alokkumar Jha, Pratheeshan Sabeshan et autres

gb, us (code pays fourni par la source)

84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer

Elghadi Ragd Sami, Pratheeshan Sabeshan, Ishita Datta, Ayush Jha et autres

gb, au (code pays fourni par la source)